InvestorsHub Logo
Followers 15
Posts 1346
Boards Moderated 0
Alias Born 07/04/2017

Re: Bed Bath & Beyonce post# 564

Tuesday, 01/16/2018 8:10:58 PM

Tuesday, January 16, 2018 8:10:58 PM

Post# of 1456
Have you checked out Auscann ACNNF they are another Aussie mj play.

As far as PUF is concerned, I think they are still in the planing stage as far as the 1 million sq ft facility is concerned.

PVA has agreed to a purchase option agreement with the Richmond Valley Council for a 27-hectare parcel of land near the town of Casino in northern New South Wales, Australia. This is a landmark agreement whereby the council will provide the land for 5 years at no cost, with an option for PVA to purchase the parcel on favorable terms after year 5. The Richmond Valley Council has been extremely supportive of PVA's growth strategy and vision and is committed to improving local economic and employment opportunities. The purchase agreement and associated partnership with the Richmond Valley Council will allow PVA to enter the cannabis market on a solid footing with the full support of the local political and governing bodies. Having the largest medical cannabis facility in the southern hemisphere in Richmond Valley is expected to draw other investments in research, education, manufacturing, tourism and other sectors.


The strategic partnership between PVA and the Richmond Valley Council accelerates PUF's aggressive global expansion strategy. The cannabis cultivation application protocols in Australia are similar to the Health Canada ACMPR process where requirements are broad and restrictive, and substantial funding is required. It includes an extensive police check, plus strict regulations on the type and amount that security cultivation facilities will require. PVA will file its formal application with the Office of Drug Control in the coming weeks and is working diligently toward becoming a licensed producer in Australia.

PUF Ventures is on the path of becoming one of the largest cannabis companies in the world. The Company is currently working through the ACMPR process with Health Canada; it has launched a biomedical cannabidiol ("CBD") product line to be manufactured in the United States and sold in Europe with a specific emphasis on Germany and Croatia; and now is planning a multi-phased build-out of a 1 million-square- foot cultivation facility in Australia, that, when complete, will have production capacity of approximately 100,000 kilograms of cannabis per year, which equates to an associated revenue generation potential of approximately C$800 Million to $1.1 Billion.